POLYPEPTIDE Trademark

Trademark Overview


On Friday, May 5, 2023, a trademark application was filed for POLYPEPTIDE with the United States Patent and Trademark Office. The USPTO has given the POLYPEPTIDE trademark a serial number of 79378525. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, September 18, 2024. This trademark is owned by Polypeptide Laboratories Holding (PPL) AB. The POLYPEPTIDE trademark is filed in the Chemical Products, Cosmetics & Cleaning Products, Pharmaceutical Products, Treatment & Processing of Materials Services, Advertising, Business and Retail Services, and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing

Synthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduct...

Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices

Advertising services; business administration; business management; providing office function

Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes

Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucelotide manufacturing
polypeptide

General Information


Serial Number79378525
Word MarkPOLYPEPTIDE
Filing DateFriday, May 5, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateWednesday, September 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 22, 2024

Trademark Statements


Goods and ServicesCustom manufacturing services for others in the field of peptide and olignuclotide manufacturing
Description of MarkThe mark consists of a stylized atomic model in green. To the right of this design is the wording "POLYPEPTIDE" in black font. The white in the mark is background only and is not claimed as a feature of the mark.
Goods and ServicesSynthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncology, neurology, rare diseases for the treatment of genetic disorders, neurodegenerative diseases and cancer; pharmaceutical and veterinary preparations, namely, synthetic peptides for pharmaceutical and veterinary purposes for fertility control in animals, induction of ovulation in mares, castration of dogs, facilitation of parturition in livestock; biological preparations for medical and veterinary purposes, namely, polypetide biochemicals for medical and veterinary purposes for oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; medicated dandruff and hair loss shampoos, medicated hair lotions for treating dandruff hair loss and hair damage, medicated soap cleansers for the skin, and medicated cosmetics, namely creams for treating acne, irritated, itching, and inflamed skin, repairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressings, namely, medical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines
Goods and ServicesNon-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices
Indication of Colors claimedThe color(s) green and black is/are claimed as a feature of the mark.
Goods and ServicesAdvertising services; business administration; business management; providing office function
Goods and ServicesBiological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes
NOT AVAILABLE"POLYPEPTIDE"
Goods and ServicesResearch and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucelotide manufacturing

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class003 - Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices.
US Class Codes001, 004, 006, 050, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code003
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, September 18, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePolypeptide Laboratories Holding (PPL) AB
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSE

Trademark Events


Event DateEvent Description
Monday, September 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 31, 2024ASSIGNED TO EXAMINER
Thursday, September 14, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, September 22, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, February 28, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, February 6, 2024NON-FINAL ACTION WRITTEN
Wednesday, February 7, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, February 28, 2024REFUSAL PROCESSED BY MPU
Wednesday, August 28, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 28, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 19, 2024REFUSAL PROCESSED BY IB
Wednesday, August 28, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 16, 2024EXAMINER'S AMENDMENT ENTERED
Monday, September 16, 2024EXAMINERS AMENDMENT -WRITTEN
Monday, September 16, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, September 16, 2024EXAMINERS AMENDMENT E-MAILED
Monday, September 16, 2024APPROVED FOR PUB - PRINCIPAL REGISTER